In this large observational claims-based study, perirectal spacer use during prostate radiotherapy was associated with reduced short-term urinary toxicities and healthcare costs, but not with a statistically significant difference in rectal toxicity, the primary FDA-approved indication.
Palencia et al. (Wed,) studied this question.